Home » Stocks » IMUX

Immunic, Inc. (IMUX)

Stock Price: $17.44 USD -2.42 (-12.19%)
Updated November 24, 4:00 PM EST - Market closed
After-hours: $17.54 +0.10 (0.57%) Nov 24, 7:59 PM

Stock Price Chart

Key Info

Market Cap 361.33M
Revenue (ttm) n/a
Net Income (ttm) -40.55M
Shares Out 20.72M
EPS (ttm) -3.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $17.44
Previous Close $19.86
Change ($) -2.42
Change (%) -12.19%
Day's Open 20.20
Day's Range 16.09 - 20.98
Day's Volume 803,248
52-Week Range 4.19 - 23.39

More Stats

Market Cap 361.33M
Enterprise Value 228.88M
Earnings Date (est) Mar 22, 2021
Ex-Dividend Date n/a
Shares Outstanding 20.72M
Float 13.56M
EPS (basic) -2.95
EPS (diluted) -3.11
FCF / Share -2.10
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 735,179
Short Ratio 2.37
Short % of Float 5.42%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.39
Revenue n/a
Operating Income -42.97M
Net Income -40.55M
Free Cash Flow -38.57M
Net Cash 132.45M
Net Cash / Share 6.39
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -26.89%
ROE -36.30%
ROIC 2,628.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$60.86*
(248.97% upside)
Low
45.0
Current: $17.44
High
72.0
Target: 60.86
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue--------
Operating Income-37.03-12.00-52.66-41.27-52.12-50.34-31.40-9.58
Net Income-34.93-11.54-52.08-40.97-52.02-47.67-32.72-6.70
Shares Outstanding7.720.851.000.780.630.400.010.01
Earnings Per Share-4.52-13.63-52.40-52.40-82.80-141.60-2,994.40-715.60
Operating Cash Flow-28.55-9.74-40.40-35.77-49.95-40.83-28.65-9.24
Capital Expenditures-0.02-0.03-0.68-0.55-2.34-1.41-1.48-0.24
Free Cash Flow-28.56-9.77-41.08-36.33-52.29-42.23-30.13-9.49
Cash & Equivalents29.3713.0756.9059.9983.9510439.1518.83
Total Debt0.52-------
Net Cash / Debt28.8513.0756.9059.9983.9510439.1518.83
Assets65.9613.3760.3864.0389.0810846.5920.33
Liabilities7.591.9210.345.586.7610.5291.2427.96
Book Value58.36-25.7450.0458.4582.3397.56-44.66-7.63
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Immunic, Inc.
Country United States
Employees 26
CEO Daniel Vitt

Stock Information

Ticker Symbol IMUX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMUX

Description

Immunic, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in Phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in Phase 2 trial to treat Crohn's disease. The company is also developing IMU-935, an inverse agonist of RORgt; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.